Endometrial Carcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (1) | dMMR | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| FDA (1) | MSI-H | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| EMA (1) FDA (1) | dMMR | Endometrial Carcinoma | Dostarlimab | |
| EMA (1) FDA (1) | dMMR | Endometrial Carcinoma | Carboplatin, Durvalumab, Paclitaxel | |
| FDA (1) | MSI-L | Endometrial Carcinoma | Lenvatinib, Pembrolizumab | |
| FDA (1) | pMMR | Endometrial Carcinoma | Pembrolizumab | |
| EMA (1) FDA (1) | MSI-H | Endometrial Carcinoma | Pembrolizumab | |
| EMA (1) | pMMR | Endometrial Carcinoma | Carboplatin, Durvalumab, Olaparib, Paclitaxel | |
| EMA (1) | MSI-H | Endometrial Carcinoma | Dostarlimab | |
| EMA (1) | dMMR | Endometrial Carcinoma | Pembrolizumab | |
| EMA (1) | pMMR | Endometrial Carcinoma | Durvalumab, Olaparib |